Breast Cancer

Chemotherapy regimen is highly active, well tolerated in advanced cases

Published in Clinical Oncology Week, May 16th, 2005

Combining weekly vinorelbine (VNB) with a weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) was found highly active in women with advanced breast cancer (ABC).

Researchers also report that the regimen was well tolerated.

For this prospective study, "vinorelbine 25 mg/m² 30-minute intravenous infusion, and high-dose 5-FU 2600 mg/m² plus LV 300 mg/m² 24-hour intravenous infusion (HDFL regimen) were given on days 1 and 8 every 3 weeks."

K.H. Yeh and colleagues, National Taiwan University Hospital, reported, "Between June 1999 and April 2003, 40 patients with histologically...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2005-05-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry